ReviewCNS neuroscience & therapeutics2018

TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia.

Kazunori Suzuki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.